NRX Pharmaceuticals
NRXP
30 hedge funds and large institutions have $2.07M invested in NRX Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 4 closing their positions.
738% more call options, than puts
Call options by funds: $109K | Put options by funds: $13K
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
0.02% less ownership
Funds ownership: 0.46% → 0.44% (-0.02%)
9% less funds holding
Funds holding: 33 → 30 (-3)
40% less capital invested
Capital invested by funds: $3.44M → $2.07M (-$1.36M)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$53.6K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$52.7K |
| 3 |
VF
Virtu Financial
New York
|
+$46.8K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$35.5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$18.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWM
AE Wealth Management
Topeka,
Kansas
|
-$32.8K |
| 2 |
ETC
Exchange Traded Concepts
Oklahoma City,
Oklahoma
|
-$29.9K |
| 3 |
HSA
HBK Sorce Advisory
Erie,
Pennsylvania
|
-$29.6K |
| 4 |
HF
HRT Financial
New York
|
-$29K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$25.5K |
NRXP Hedge Fund Activity: Q1 2023 in Review
30 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q1 2023, worth a combined $2.07M — down 40% from $3.44M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of NRXP and 2 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 10 added.
The largest buyer was Susquehanna International Group, adding an estimated $53.6K. The largest seller was AE Wealth Management, exiting entirely with an estimated $32.8K sold.
- 30 institutional investors held NRX Pharmaceuticals (NRXP) as of Q1 2023, down from 33 in Q4 2022.
- Funds reported $2.07M of NRX Pharmaceuticals stock for Q1 2023, down 40% quarter-over-quarter.
- 2 funds opened new NRX Pharmaceuticals positions in Q1 2023 and 4 closed out, a net change of -2 holders.
- The largest NRX Pharmaceuticals buyer in Q1 2023 was Susquehanna International Group, an estimated $53.6K added.
- The largest NRX Pharmaceuticals seller in Q1 2023 was AE Wealth Management, an estimated $32.8K sold.
Based on aggregated 13F filings for Q1 2023.